Faster-acting insulin aspart provides faster onset and g
aspart in children and adolescents with type 1 diabetes

Pediatric Diabetes

18, 903-910

DOI: 10.1111/pedi.12506

Citation Report

#	Article	IF	Citations
1	Diabetes Technology and Therapy in the Pediatric Age Group. Diabetes Technology and Therapeutics, 2016, 18, S-86-S-100.	2.4	2
2	A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes. Clinical Pharmacokinetics, 2017, 56, 551-559.	1.6	150
3	Insulin analogues in type 1 diabetes mellitus: getting better all the time. Nature Reviews Endocrinology, 2017, 13, 385-399.	4.3	170
4	Pharmacotherapy options for pediatric diabetes. Current Opinion in Pediatrics, 2017, 29, 481-487.	1.0	2
5	Pharmacological Properties of Faster-Acting Insulin Aspart. Current Diabetes Reports, 2017, 17, 101.	1.7	20
8	Efficacy and Safety of Rapid-Acting Insulin Analogs in Special Populations with Type 1 Diabetes or Gestational Diabetes: Systematic Review and Meta-Analysis. Diabetes Therapy, 2018, 9, 891-917.	1.2	21
9	The challenges of achieving postprandial glucose control using closedâ€loop systems in patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 245-256.	2.2	79
11	Pharmacotherapy of type1 diabetes in children and adolescents: more than insulin?. Therapeutic Advances in Endocrinology and Metabolism, 2018, 9, 157-166.	1.4	6
12	ISPAD Clinical Practice Consensus Guidelines 2018: Insulin treatment in children and adolescents with diabetes. Pediatric Diabetes, 2018, 19, 115-135.	1.2	164
13	Faster Insulin Aspart: A New Bolus Option for Diabetes Mellitus. Clinical Pharmacokinetics, 2019, 58, 421-430.	1.6	19
14	Insulin Pumps and Artificial Pancreas. , 2019, , 245-258.		1
15	Pharmacotherapy of Children and Adolescents with Type 1 Diabetes Mellitus. Handbook of Experimental Pharmacology, 2019, 261, 105-118.	0.9	2
16	Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin. Diabetes Therapy, 2019, 10, 1793-1800.	1.2	11
17	Use of fastâ€acting insulin aspart in insulin pump therapy in clinical practice. Diabetes, Obesity and Metabolism, 2019, 21, 2039-2047.	2.2	41
18	Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial. Diabetes Care, 2019, 42, 1255-1262.	4.3	41
19	Fast-Acting Insulin Aspart and the Need for New Mealtime Insulin Analogues in Adults With Type 1 and Type 2 Diabetes: A Canadian Perspective. Canadian Journal of Diabetes, 2019, 43, 515-523.	0.4	32
20	Single-Hormone Artificial Pancreas Use in Diabetes: Clinical Efficacy and Remaining Challenges. Diabetes Spectrum, 2019, 32, 205-208.	0.4	7
21	Role of ultrafast-acting insulin analogues in the management of diabetes. Journal of the American Association of Nurse Practitioners, 2019, 31, 537-548.	0.5	9

#	Article	IF	Citations
22	Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences. Clinical Pharmacokinetics, 2020, 59, 155-172.	1.6	35
23	Insulin Pump Therapy. American Journal of Therapeutics, 2020, 27, e30-e41.	0.5	46
24	The association between antiâ€insulin aspart antibodies and the pharmacokinetic and pharmacodynamic characteristics of fastâ€acting insulin aspart in children and adolescents with type 1 diabetes. Pediatric Diabetes, 2020, 21, 781-790.	1.2	3
25	An ultrafast insulin formulation enabled by high-throughput screening of engineered polymeric excipients. Science Translational Medicine, 2020, 12, .	5.8	46
26	The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications. Diabetes, Obesity and Metabolism, 2020, 22, 743-754.	2.2	50
27	Efficacy and safety of fast-acting insulin aspart <i>versus</i> insulin aspart in children and adolescents with type 1 diabetes from Japan. Endocrine Journal, 2021, 68, 409-420.	0.7	2
29	Diabetes Technology and Therapy in the Pediatric Age Group. Diabetes Technology and Therapeutics, 2021, 23, S-113-S-130.	2.4	0
30	New Insulins, Biosimilars, and Insulin Therapy. Diabetes Technology and Therapeutics, 2021, 23, S-46-S-68.	2.4	5
31	Si l'Ã¨re des insulines semi-synthÃ©tiques et biosynthÃ©tiques nous Ã©tait contÃ©e. Medecine Des Maladies Metaboliques, 2021, 15, 3S32-3S52.	0.1	1
32	Ultraâ€Fast Insulinâ€“Pramlintide Coâ€Formulation for Improved Glucose Management in Diabetic Rats. Advanced Science, 2021, 8, e2101575.	5.6	10
33	Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study. Diabetes, Obesity and Metabolism, 2020, 22, 1789-1798.	2.2	49
34	The Diabits App for Smartphone-Assisted Predictive Monitoring of Glycemia in Patients With Diabetes: Retrospective Observational Study. JMIR Diabetes, 2020, 5, e18660.	0.9	11
36	The impact of â€œfaster aspartâ€•on blood glucose control in children and adolescents with type 1 diabetes treated using a sensor-augmented insulin pump. Anales De PediatrÃa (English Edition), 2021, 95, 321-329.	0.1	0
37	Evolving Pharmacotherapeutic Strategies for Type 1 Diabetes Mellitus. Journal of Pediatric Pharmacology and Therapeutics, 2018, 23, 351-361.	0.3	1
38	ThÃ©rapeutique des dÃ©sordres glycÃ©miques. , 2019, , 141-252.		0
39	Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences. Diabetes Mellitus, 2020, 23, 140-160.	0.5	0
40	The effectiveness of insulin therapy in children with type 1 diabetes in Ukraine according to the register of patients. Ukrainian Journal of Pediatric Endocrinology, 2020, .	0.1	0
41	ISPAD Clinical Practice Consensus Guidelines 2018. Chapter 9. Insulin treatment in children and adolescents with diabetes. Ukrainian Journal of Pediatric Endocrinology, 2020, .	0.1	0

#	Article	IF	Citations
44	Ultrafast acting insulin analog â€“ aÂnew way to prevent postprandial hyperglycemia and improve quality of life in type 1 diabetes patients â€“ case reports. Pediatric Endocrinology, Diabetes and Metabolism, 2021, 27, 305-310.	0.3	5
45	Super Bolus: a remedy for a high glycemic index meal in children with type 1 diabetes on insulin pump therapy?â€"study protocol for a randomized controlled trial. Trials, 2022, 23, 240.	0.7	4
46	<scp>Rapidâ€acting</scp> insulin analogues: Theory and best clinical practice in type 1 and type 2 diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 63-74.	2.2	4
47	The Effect of Two Different Insulin Formulations on Postprandial Hyperglycemia after High and Low Glycemic-Index Meal in Type 1 Diabetes. Nutrients, 2022, 14, 3316.	1.7	1
48	Adjusting Therapy Profiles When Switching to Ultra-Rapid Lispro in an Advanced Hybrid Closed-Loop System: An in Silico Study. Journal of Diabetes Science and Technology, 0, , 193229682211404.	1.3	2
49	Comparative assessment of modern parameters of glycemic control in children with type 1 diabetes after switching to fast-acting insulin aspart using Flash Glucose Monitoring in real clinical practice. Diabetes Mellitus, 2022, 25, 458-467.	0.5	0
50	<scp>ISPAD</scp> Clinical Practice Consensus Guidelines 2022: Insulin treatment in children and adolescents with diabetes. Pediatric Diabetes, 2022, 23, 1277-1296.	1.2	19
51	Optimal Prandial Timing of Insulin Bolus in Youths with Type 1 Diabetes: A Systematic Review. Journal of Personalized Medicine, 2022, 12, 2058.	1.1	3
52	Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus. Diabetes, Obesity and Metabolism, 2023, 25, 1964-1972.	2.2	3